Phase 2 Osteoarthritis Trial, Recruiting NCT07580716 Sponsor: Enlivex Therapeutics Ltd. Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT07580716
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 64 years or older
  • People who have been diagnosed with knee osteoarthritis (OA) affecting the joint between the thigh bone and shin bone (the main knee joint)
  • People whose knee osteoarthritis has been confirmed by X-ray, showing a moderate level of joint changes (a specific grading system score of 2 or 3)
  • People who have already tried at least 2 treatments for osteoarthritis without enough relief, or who were unable to tolerate those treatments
  • People whose knee pain has been assessed during the screening period, after stopping any pain medications for a set washout period
  • People who are willing to avoid certain medications or treatments that are not permitted during the trial
  • Women who have gone through menopause naturally (no period for 12 months or more, with no other explanation) or who have had a surgical procedure that means they cannot become pregnant (such as removal of the ovaries, tubes tied, or hysterectomy)
  • Male participants whose partners could become pregnant, and who are not surgically sterilised (vasectomy for at least 6 months before joining the trial), must use condoms with spermicide in addition to their partner's contraception from the start of the trial until 90 days after the last dose

Who may not be able to join:

  • People with very severe or end-stage osteoarthritis in the affected knee
  • People who have significant structural problems or instability in the affected knee
  • People who have had a major injury, surgery, or injection treatment in the affected knee recently
  • People with a known history of infection or a tumour in the affected knee, or who currently have an infection at the planned injection site
  • People with a known history of inflammatory joint disease (such as rheumatoid arthritis) or conditions where crystals build up in the joints (such as gout)
  • People with a serious widespread condition affecting cartilage, bone, or muscles that could affect the trial results
  • People with significant widespread pain conditions affecting multiple areas of the body
  • People who are taking medications that suppress the immune system, have a significant immune deficiency, or currently have an active infection
  • People with a Body Mass Index (BMI) — a measure of body weight relative to height — above 40
  • People taking medications that could interfere with pain measurement or other trial results
  • People with known blood clotting disorders, or who take blood-thinning or anti-clotting medications
  • People with significant uncontrolled health conditions, or who have notable abnormal findings on screening blood tests or physical examination

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lital Weinfeld Bergman, Senior Director of Clinical Operations

Phone: +972-54-8054599

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Enlivex Therapeutics Ltd.
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 February 2027

Where this trial is recruiting

🇩🇰 Denmark 🇵🇱 Poland 🇺🇸 United States

Primary endpoints

Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain score at 3 months; Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function score at 3 months; Primary Safety Endpoint

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov